Panagora Asset Management’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-49,119
Closed -$13K 2827
2019
Q2
$13K Hold
49,119
﹤0.01% 2366
2019
Q1
$11K Sell
49,119
-28,022
-36% -$6.28K ﹤0.01% 2357
2018
Q4
$19K Buy
77,141
+12,218
+19% +$3.01K ﹤0.01% 2233
2018
Q3
$16K Buy
64,923
+25,232
+64% +$6.22K ﹤0.01% 2259
2018
Q2
$10K Hold
39,691
﹤0.01% 2274
2018
Q1
$10K Hold
39,691
﹤0.01% 2265
2017
Q4
$11K Sell
39,691
-2,234
-5% -$619 ﹤0.01% 2223
2017
Q3
$10K Sell
41,925
-9,355
-18% -$2.23K ﹤0.01% 2238
2017
Q2
$19K Hold
51,280
﹤0.01% 2297
2017
Q1
$12K Hold
51,280
﹤0.01% 2253
2016
Q4
$19K Hold
51,280
﹤0.01% 2235
2016
Q3
$19K Buy
+51,280
New +$19K ﹤0.01% 2272
2014
Q2
Sell
-151,905
Closed -$156K 2453
2014
Q1
$156K Hold
151,905
﹤0.01% 1814
2013
Q4
$176K Sell
151,905
-1,900
-1% -$2.93K ﹤0.01% 1709
2013
Q3
$258K Sell
153,805
-21,862
-12% -$40.5K ﹤0.01% 1565
2013
Q2
$349K Buy
+175,667
New +$514K ﹤0.01% 1430

Panagora Asset Management's ENZN Position: Q3 2019 in Review

Panagora Asset Management sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q3 2019, closing a stake of 49,119 shares — an estimated $13K sold.

Panagora Asset Management first reported a position in ENZN in Q2 2013 and held it in 16 quarters. The position peaked at $349K in Q2 2013. 0 funds tracked by Wall St. Rank hold ENZN as of Q3 2019.

  • Panagora Asset Management reported no remaining ENZON PHARMACEUTICALS INC position as of Q3 2019 after selling out during the quarter.
  • Panagora Asset Management sold 49,119 ENZON PHARMACEUTICALS INC shares in Q3 2019, an estimated $13K.
  • Panagora Asset Management first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 16 quarters.
  • Panagora Asset Management's ENZON PHARMACEUTICALS INC position peaked at $349K in Q2 2013.
  • 0 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.